Active, not recruitingPhase 4NCT05181475

Long-term Efficacy and Safety Study of GV-971

Studying Cap myopathy

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Intervention: Sodium Oligomannate Capsules (GV-971)(drug)
Enrollment: 800 enrolled
Eligibility: 50-85 years · All sexes
Timeline: 2021 – 2025

Study locations (30)

Beijing Chao-Yang Hospital, Beijing, Beijing Municipality, China
Peking University Shougang Hospital, Beijing, Beijing Municipality, China
Peking University Third Hospital, Beijing, Beijing Municipality, China
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
Lanzhou University Second Hospital, Lanzhou, Gansu, China
The First Hospital of Lanzhou University, Lanzhou, Gansu, China
The First People's Hospital of Foshan, Foshan, Guangdong, China
Nanfang Hospital, Guangzhou, Guangdong, China
The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Shenzhen People's Hospital, Shenzhen, Guangdong, China
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
No.6 HeBei Provincial People's Hospital, Baoding, Hebei, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05181475 on ClinicalTrials.gov

Other trials for Cap myopathy

Additional recruiting or active studies for the same condition.

See all trials for Cap myopathy →

← Back to all trials